Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
1 result
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Clin Pharmacol Drug Dev. 2023 May;12(5):525-534. doi: 10.1002/cpdd.1243. Epub 2023 Mar 20.
Clin Pharmacol Drug Dev. 2023.
PMID: 36938862
Clinical Trial.
Cite
Cite